XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2022
Apr. 17, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Registrant Name CATALYST PHARMACEUTICALS, INC    
Entity Central Index Key 0001369568    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity Filer Category Accelerated Filer    
Trading Symbol No    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Address, State or Province FL    
Entity Interactive Data Current Yes    
Title of 12(b) Security Common Stock    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   105,976,959  
Entity Tax Identification Number 76-0837053    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 355 Alhambra Circle    
Entity Address, Address Line Two Suite 801    
Entity Address, City or Town Coral Gables    
Entity Address, Postal Zip Code 33134    
City Area Code 305    
Local Phone Number 420-3200    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-33057    
Entity Public Float     $ 665,590,948
ICFR Auditor Attestation Flag true    
Auditor Name Grant Thornton LLP    
Auditor Firm ID 248    
Auditor Location Miami, FL    
Amendment Description This Amendment No. 1 on Form 10-K/A (“Form 10-K/A”) is being filed by Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) in order to disclose information required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which information was previously omitted from Catalyst’s Form 10-K for the fiscal year ended December 31, 2022 (“2022 Original Form 10-K”) in reliance on Instruction G to Form 10-K . The 2022 Original Form 10-K was filed with the SEC on March 15, 2023. Catalyst has elected to postpone its 2023 annual meeting of stockholders until later in 2023. As a result, Catalyst will not be filing its definitive proxy statement for the 2023 annual stockholders’ meeting within 120 days of the end of its most recent fiscal year (as required under Instruction G to Form 10-K). Therefore, Catalyst is filing this Form 10-K/A in order to incorporate information that would have been contained in the definitive proxy statement into the 2022 Original Form 10-K. Catalyst is also filing as Exhibits to the Form 10-K/A certifications with respect to this filing by its principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form 10-K/A, and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Catalyst is also not including the certifications required under Section 906 of the Sarbanes-Oxley Act of 2002, since no financial statements are being filed with this Form 10-K/A. This Form 10-K/A is limited in scope to the items identified above and should be read in conjunction with the 2022 Original Form 10-K and Catalyst’s other filings with the SEC. This Form 10-K/A does not reflect events occurring after the filing of the 2022 Original Form 10-K or modify or update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures made at the time of the filing of the 2022 Original Form 10-K.